Key Highlights
- Vasa Therapeutics closes series seed funding led by Orphinic Scientific with participation from NuFund Venture Group and others.
- VS-041, a potential game-changer in HFpEF treatment, is nearing the final stages of preclinical development.
- Orphinic Scientific’s chairman, Prof. Jarosław Leszczyszyn, joins Vasa’s board, reinforcing the strategic partnership.
Source: PR Newswire
Notable Quotes
- “We are delighted to gain support from a high-quality group of US and international investors who share Vasa’s mission to develop transformative therapies for cardiovascular aging that could extend the healthy lifespan.” – Artur Plonowski, MD, PhD, CEO and Co-founder at Vasa Therapeutics
- “We are excited to have led the seed financing for Vasa. The company’s novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement.” – Adam Kruszewski, CEO at Orphinic
SoH's Take
The closing of Vasa Therapeutics’ series seed funding, particularly led by an early-stage investor like Orphinic Scientific SA, is a strong testament to the potential of their innovative approach to combating cardiovascular aging. Vasa’s lead candidate, VS-041, is poised to address the critical gap in effective treatment for heart failure with preserved ejection fraction (HFpEF), a condition notoriously difficult to manage. The investment and the addition of Prof. Jarosław Leszczyszyn to the board underline the industry’s confidence in Vasa’s science and strategy. As the biopharmaceutical industry continues to pivot towards personalized and targeted therapies, Vasa’s progression into clinical trials will be closely watched by both investors and medical professionals, marking a significant step forward in addressing the growing challenge of cardiovascular diseases associated with aging.
